Published in J Virol on January 01, 2000
Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239. J Virol (2006) 4.68
Viral shape-shifting: norovirus evasion of the human immune system. Nat Rev Microbiol (2010) 2.53
Vaccine-induced cellular responses control simian immunodeficiency virus replication after heterologous challenge. J Virol (2009) 2.38
Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140. J Virol (2001) 2.16
Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates. Expert Rev Vaccines (2006) 1.88
Heterologous gene expression from transmissible gastroenteritis virus replicon particles. J Virol (2002) 1.85
Protection against mucosal simian immunodeficiency virus SIV(mac251) challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting. J Virol (2004) 1.83
Vaccine efficacy in senescent mice challenged with recombinant SARS-CoV bearing epidemic and zoonotic spike variants. PLoS Med (2006) 1.78
Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses. J Virol (2001) 1.66
Expression and self-assembly of norwalk virus capsid protein from venezuelan equine encephalitis virus replicons. J Virol (2002) 1.60
Mucosal priming of simian immunodeficiency virus-specific cytotoxic T-lymphocyte responses in rhesus macaques by the Salmonella type III secretion antigen delivery system. J Virol (2003) 1.60
Severe acute respiratory syndrome coronavirus papain-like protease ubiquitin-like domain and catalytic domain regulate antagonism of IRF3 and NF-kappaB signaling. J Virol (2009) 1.58
trans-Packaged West Nile virus-like particles: infectious properties in vitro and in infected mosquito vectors. J Virol (2004) 1.57
An alphavirus replicon particle chimera derived from venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector. J Virol (2003) 1.56
Mucosal and systemic adjuvant activity of alphavirus replicon particles. Proc Natl Acad Sci U S A (2006) 1.49
Expression and immunogenicity of human immunodeficiency virus type 1 Gag expressed by a replication-competent rhabdovirus-based vaccine vector. J Virol (2001) 1.37
Systemic, mucosal, and heterotypic immune induction in mice inoculated with Venezuelan equine encephalitis replicons expressing Norwalk virus-like particles. J Virol (2002) 1.36
Novel adeno-associated virus vector vaccine restricts replication of simian immunodeficiency virus in macaques. J Virol (2005) 1.36
Correlation between env V1/V2 region diversification and neutralizing antibodies during primary infection by simian immunodeficiency virus sm in rhesus macaques. J Virol (2004) 1.32
Systemic neutralizing antibodies induced by long interval mucosally primed systemically boosted immunization correlate with protection from mucosal SHIV challenge. Virology (2008) 1.26
Protection against simian immunodeficiency virus vaginal challenge by using Sabin poliovirus vectors. J Virol (2001) 1.24
Induction of primary virus-cross-reactive human immunodeficiency virus type 1-neutralizing antibodies in small animals by using an alphavirus-derived in vivo expression system. J Virol (2003) 1.23
Candidate vaccine against botulinum neurotoxin serotype A derived from a Venezuelan equine encephalitis virus vector system. Infect Immun (2001) 1.20
Modulation of disease, T cell responses, and measles virus clearance in monkeys vaccinated with H-encoding alphavirus replicon particles. Proc Natl Acad Sci U S A (2005) 1.16
Alpha-beta T cells provide protection against lethal encephalitis in the murine model of VEEV infection. Virology (2007) 1.16
Recombinant yellow fever vaccine virus 17D expressing simian immunodeficiency virus SIVmac239 gag induces SIV-specific CD8+ T-cell responses in rhesus macaques. J Virol (2010) 1.16
Tetraspanins in viral infections: a fundamental role in viral biology? J Virol (2005) 1.16
Alphavirus replicon approach to promoterless analysis of IRES elements. Virology (2006) 1.15
Humoral responses against coimmunized protein antigen but not against alphavirus-encoded antigens require alpha/beta interferon signaling. J Virol (2006) 1.15
Kunjin virus replicon vaccine vectors induce protective CD8+ T-cell immunity. J Virol (2002) 1.14
Cellular and humoral immune responses to alphavirus replicon vaccines expressing cytomegalovirus pp65, IE1, and gB proteins. Clin Vaccine Immunol (2007) 1.08
Prevention of disease induced by a partially heterologous AIDS virus in rhesus monkeys by using an adjuvanted multicomponent protein vaccine. J Virol (2003) 1.06
DNA vaccines against human immunodeficiency virus type 1 in the past decade. Clin Microbiol Rev (2004) 1.06
Significant protection against high-dose simian immunodeficiency virus challenge conferred by a new prime-boost vaccine regimen. J Virol (2011) 1.05
Comparison of multiple vaccine vectors in a single heterologous prime-boost trial. Vaccine (2008) 1.03
Targeting novel antigens for prostate cancer treatment: focus on prostate-specific membrane antigen. Expert Opin Ther Targets (2005) 1.01
Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cells. J Virol (2005) 1.01
Alphavirus replicon particles acting as adjuvants promote CD8+ T cell responses to co-delivered antigen. Vaccine (2008) 0.99
N-linked glycans on dengue viruses grown in mammalian and insect cells. J Gen Virol (2009) 0.97
An immunogenic and protective alphavirus replicon particle-based dengue vaccine overcomes maternal antibody interference in weanling mice. J Virol (2007) 0.95
Antigen sparing with adjuvanted inactivated polio vaccine based on Sabin strains. Vaccine (2013) 0.93
The contribution of type I interferon signaling to immunity induced by alphavirus replicon vaccines. Vaccine (2008) 0.92
Nonmucosal alphavirus vaccination stimulates a mucosal inductive environment in the peripheral draining lymph node. J Immunol (2008) 0.92
Alphavirus replicon-based enhancement of mucosal and systemic immunity is linked to the innate response generated by primary immunization. Vaccine (2010) 0.92
Vaccination of mice with gonococcal TbpB expressed in vivo from Venezuelan equine encephalitis viral replicon particles. Infect Immun (2006) 0.92
Vaccination with Venezuelan equine encephalitis replicons encoding cowpox virus structural proteins protects mice from intranasal cowpox virus challenge. Virology (2007) 0.91
Expression of LIGHT/TNFSF14 combined with vaccination against human papillomavirus Type 16 E7 induces significant tumor regression. Cancer Res (2010) 0.90
Phase I safety and immunogenicity evaluations of an alphavirus replicon HIV-1 subtype C gag vaccine in healthy HIV-1-uninfected adults. Clin Vaccine Immunol (2012) 0.89
Infected dendritic cells are sufficient to mediate the adjuvant activity generated by Venezuelan equine encephalitis virus replicon particles. Vaccine (2012) 0.88
Challenges in the search for an HIV vaccine. Eur J Epidemiol (2004) 0.87
Alphavirus replicon particles containing the gene for HER2/neu inhibit breast cancer growth and tumorigenesis. Breast Cancer Res (2004) 0.85
Analysis of Venezuelan equine encephalitis replicon particles packaged in different coats. PLoS One (2008) 0.84
Induction of neutralizing antibodies to Hendra and Nipah glycoproteins using a Venezuelan equine encephalitis virus in vivo expression system. Vaccine (2010) 0.81
An alphavirus-based adjuvant enhances serum and mucosal antibodies, T cells, and protective immunity to influenza virus in neonatal mice. J Virol (2014) 0.80
A mucosal adjuvant for the inactivated poliovirus vaccine. Vaccine (2013) 0.80
Effects of rapid antigen degradation and VEE glycoprotein specificity on immune responses induced by a VEE replicon vaccine. Virology (2007) 0.79
A human dendritic cell subset receptive to the Venezuelan equine encephalitis virus-derived replicon particle constitutively expresses IL-32. J Immunol (2008) 0.79
Structure and immunogenicity of alternative forms of the simian immunodeficiency virus gag protein expressed using Venezuelan equine encephalitis virus replicon particles. Virology (2007) 0.78
Development and evaluation of a replicon particle vaccine expressing the E2 glycoprotein of bovine viral diarrhea virus (BVDV) in cattle. Virol J (2013) 0.77
Lower levels of gamma interferon expressed by a pseudotyped single-cycle simian immunodeficiency virus enhance immunogenicity in rats. J Virol (2008) 0.76
New applications of alphavirus-based expression vectors. Cytotechnology (2001) 0.75
Dendritic cells and the control of immunity. Nature (1998) 56.54
General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes. J Virol (1984) 10.98
A new generation of animal cell expression vectors based on the Semliki Forest virus replicon. Biotechnology (N Y) (1991) 7.08
Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques. Science (1995) 6.30
Sindbis virus: an efficient, broad host range vector for gene expression in animal cells. Science (1989) 4.84
The extent of early viral replication is a critical determinant of the natural history of simian immunodeficiency virus infection. J Virol (1997) 3.77
Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo. Virology (1997) 3.62
Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers. Proc Natl Acad Sci U S A (1997) 3.02
Infectious Sindbis virus transient expression vectors for studying antigen processing and presentation. Proc Natl Acad Sci U S A (1992) 2.86
Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160. Science (1992) 2.83
Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates. Virology (1998) 2.81
Human immunodeficiency virus type 1 Gag proteins are processed in two cellular compartments. Proc Natl Acad Sci U S A (1991) 2.80
Role of dendritic cell targeting in Venezuelan equine encephalitis virus pathogenesis. J Virol (2000) 2.67
Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines. J Virol (1998) 2.63
Pathogenic diversity of simian immunodeficiency viruses. Virus Res (1994) 2.27
Specific restrictions in the progression of Venezuelan equine encephalitis virus-induced disease resulting from single amino acid changes in the glycoproteins. Virology (1995) 2.14
Protection against lethal simian immunodeficiency virus SIVsmmPBj14 disease by a recombinant Semliki Forest virus gp160 vaccine and by a gp120 subunit vaccine. J Virol (1996) 2.12
Evaluation of avian-human reassortant influenza A/Washington/897/80 x A/Pintail/119/79 virus in monkeys and adult volunteers. J Clin Microbiol (1986) 2.06
Recombinant vaccine-induced protection against the highly pathogenic simian immunodeficiency virus SIV(mac251): dependence on route of challenge exposure. J Virol (1998) 1.98
Translation of Sindbis virus mRNA: analysis of sequences downstream of the initiating AUG codon that enhance translation. J Virol (1996) 1.89
Humoral, mucosal, and cellular immunity in response to a human immunodeficiency virus type 1 immunogen expressed by a Venezuelan equine encephalitis virus vaccine vector. J Virol (1997) 1.73
Simian immunodeficiency virus DNA vaccine trial in macaques. J Virol (1996) 1.71
A viral vaccine vector that expresses foreign genes in lymph nodes and protects against mucosal challenge. J Virol (1996) 1.68
Human immunodeficiency virus type 1-specific cytotoxic T lymphocyte activity is inversely correlated with HIV type 1 viral load in HIV type 1-infected long-term survivors. AIDS Res Hum Retroviruses (1999) 1.66
Neutralizing and infection-enhancing antibody responses do not correlate with the differential pathogenicity of SIVmac239delta3 in adult and infant rhesus monkeys. J Immunol (1996) 1.65
Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group. J Infect Dis (1998) 1.64
Weakened SIV vaccine still kills. Science (1997) 1.57
Attenuated mutants of Venezuelan equine encephalitis virus containing lethal mutations in the PE2 cleavage signal combined with a second-site suppressor mutation in E1. Virology (1995) 1.57
A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). The AGIS Group, and l'Agence Nationale de Recherche sur le SIDA. AIDS Res Hum Retroviruses (1995) 1.56
Immunization with whole inactivated vaccine protects from infection by SIV grown in human but not macaque cells. J Med Primatol (1994) 1.45
Direct and quantitative detection of HIV-1 RNA in human plasma with a branched DNA signal amplification assay. AIDS (1993) 1.42
Stable alphavirus packaging cell lines for Sindbis virus and Semliki Forest virus-derived vectors. Proc Natl Acad Sci U S A (1999) 1.38
Self-replicating Semliki Forest virus RNA as recombinant vaccine. Vaccine (1994) 1.30
Mucosal immunity induced by parenteral immunization with a live attenuated Venezuelan equine encephalitis virus vaccine candidate. Virology (1997) 1.22
Generation of cytotoxic and humoral immune responses by nonreplicative recombinant Semliki Forest virus. Proc Natl Acad Sci U S A (1995) 1.21
Outcome of immunization of cynomolgus monkeys with recombinant Semliki Forest virus encoding human immunodeficiency virus type 1 envelope protein and challenge with a high dose of SHIV-4 virus. AIDS Res Hum Retroviruses (1997) 1.16
AIDS vaccine development in primate models. AIDS (1998) 1.12
Protective efficacies of live attenuated and formaldehyde-inactivated Venezuelan equine encephalitis virus vaccines against aerosol challenge in hamsters. J Clin Microbiol (1984) 1.11
Recombinant vaccinia virus/Venezuelan equine encephalitis (VEE) virus protects mice from peripheral VEE virus challenge. J Virol (1988) 1.10
A comparison of live and inactivated influenza A (H1N1) virus vaccines. 1. Short-term immunity. J Hyg (Lond) (1983) 1.07
Molecular cloning of SIV from sooty mangabey monkeys. J Med Primatol (1989) 1.02
Roles of the six peptide-binding pockets of the HLA-A2 molecule in allorecognition by human cytotoxic T-cell clones. Proc Natl Acad Sci U S A (1993) 1.01
Experimental studies of rhesus monkeys infected with epizootic and enzootic subtypes of Venezuelan equine encephalitis virus. J Infect Dis (1974) 0.98
Strategies for AIDS vaccines. J Antimicrob Chemother (1996) 0.90
Recombinant subunit vaccines as an approach to study correlates of protection against primate lentivirus infection. Immunol Lett (1996) 0.87
Characterization of the expression and immunogenicity of poliovirus replicons that encode simian immunodeficiency virus SIVmac239 Gag or envelope SU proteins. AIDS Res Hum Retroviruses (1997) 0.84
AIDS 1998. Vaccines and immunology: overview. AIDS (1998) 0.79
Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science (1999) 21.24
X-ray intensifying screens greatly enhance the detection by autoradiography of the radioactive isotopes 32P and 125I. Anal Biochem (1978) 10.28
Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science (2000) 9.92
Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science (2001) 9.09
Complete mutagenesis of the HIV-1 protease. Nature (1989) 5.16
An African primate lentivirus (SIVsm) closely related to HIV-2. Nature (1989) 5.03
The G glycoprotein of human respiratory syncytial viruses of subgroups A and B: extensive sequence divergence between antigenically related proteins. Proc Natl Acad Sci U S A (1987) 4.93
Diffraction enhanced x-ray imaging. Phys Med Biol (1997) 4.63
New lymphocyte antigen system (Lna) controlled by the Ir region of the mouse H-2 complex. Proc Natl Acad Sci U S A (1973) 4.45
Quantitating the multiplicity of infection with human immunodeficiency virus type 1 subtype C reveals a non-poisson distribution of transmitted variants. J Virol (2009) 4.40
Retrovirus envelope glycoproteins. Curr Top Microbiol Immunol (1990) 4.22
Assessment of thymic output in adults after haematopoietic stem-cell transplantation and prediction of T-cell reconstitution. Lancet (2000) 4.17
Characterization of V3 sequence heterogeneity in subtype C human immunodeficiency virus type 1 isolates from Malawi: underrepresentation of X4 variants. J Virol (1999) 4.16
Expression of the F glycoprotein of respiratory syncytial virus by a recombinant vaccinia virus: comparison of the individual contributions of the F and G glycoproteins to host immunity. Proc Natl Acad Sci U S A (1986) 4.14
ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency. J Virol (2002) 4.11
The p2 domain of human immunodeficiency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectious virions. J Virol (1994) 3.95
Nucleotide sequence of cloned unintegrated avian sarcoma virus DNA: viral DNA contains direct and inverted repeats similar to those in transposable elements. Proc Natl Acad Sci U S A (1981) 3.82
Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet (1992) 3.76
Immunopathogenic events in acute infection of rhesus monkeys with simian immunodeficiency virus of macaques. J Virol (1994) 3.71
Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo. Virology (1997) 3.62
Evidence for the expression of Ia (H-2-associated) antigens on thymus-derived lymphocytes. J Exp Med (1974) 3.56
Adaptation of Sindbis virus to BHK cells selects for use of heparan sulfate as an attachment receptor. J Virol (1998) 3.51
Expression and processing of the AIDS virus reverse transcriptase in Escherichia coli. Science (1987) 3.46
Transduction of a cellular oncogene: the genesis of Rous sarcoma virus. Proc Natl Acad Sci U S A (1983) 3.41
Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection. J Infect Dis (1997) 3.35
Antibody-dependent enhancement of human immunodeficiency virus type 1 infection. Lancet (1988) 3.32
A simple, rapid method for the purification of poly A+ RNA. Biotechniques (1988) 3.22
The nucleotide sequence of an untranslated but conserved domain at the 3' end of the avian sarcoma virus genome. Nucleic Acids Res (1980) 3.16
Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses (2000) 3.13
An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis. J Exp Med (1990) 3.09
SIV adaptation to human cells. Nature (1989) 3.09
LCMV-specific, class II-restricted cytotoxic T cells in beta 2-microglobulin-deficient mice. Science (1992) 2.98
Partial inhibition of the human immunodeficiency virus type 1 protease results in aberrant virus assembly and the formation of noninfectious particles. J Virol (1993) 2.96
Induction of AIDS by simian immunodeficiency virus from an African green monkey: species-specific variation in pathogenicity correlates with the extent of in vivo replication. J Virol (1995) 2.96
Analysis of human immunodeficiency virus type 1 nef gene sequences present in vivo. J Virol (1993) 2.94
Decay kinetics of human immunodeficiency virus-specific CD8+ T cells in peripheral blood after initiation of highly active antiretroviral therapy. J Virol (2001) 2.93
Plasma viremia in macaques infected with simian immunodeficiency virus: plasma viral load early in infection predicts survival. J Virol (1997) 2.81
Human immunodeficiency virus type 1 Gag proteins are processed in two cellular compartments. Proc Natl Acad Sci U S A (1991) 2.80
The antibody response in HIV-1 infection. AIDS (1997) 2.79
Macrophage tropism of human immunodeficiency virus type 1 isolates from brain and lymphoid tissues predicts neurotropism independent of coreceptor specificity. J Virol (2001) 2.79
Efficiency of gene transfer for restoration of normal airway epithelial function in cystic fibrosis. Nat Genet (1992) 2.79
Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations. Nat Med (1999) 2.77
Improved success of phenotype prediction of the human immunodeficiency virus type 1 from envelope variable loop 3 sequence using neural networks. Virology (2001) 2.74
Highly purified recombinant adeno-associated virus vectors are biologically active and free of detectable helper and wild-type viruses. Hum Gene Ther (1999) 2.73
Three-dimensional structure of a membrane-containing virus. Proc Natl Acad Sci U S A (1993) 2.71
Species-specific diversity among simian immunodeficiency viruses from African green monkeys. J Virol (1991) 2.70
Highly attenuated vaccine strains of simian immunodeficiency virus protect against vaginal challenge: inverse relationship of degree of protection with level of attenuation. J Virol (1999) 2.69
Role of dendritic cell targeting in Venezuelan equine encephalitis virus pathogenesis. J Virol (2000) 2.67
Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination. J Virol (2001) 2.66
Protection by live, attenuated simian immunodeficiency virus against heterologous challenge. J Virol (1999) 2.65
Cleavage of HIV-1 gag polyprotein synthesized in vitro: sequential cleavage by the viral protease. AIDS Res Hum Retroviruses (1989) 2.62
Diet-induced adipocyte number increase in adult rats: a new model of obesity. Am J Physiol (1978) 2.62
Mutations in the E2 glycoprotein of Venezuelan equine encephalitis virus confer heparan sulfate interaction, low morbidity, and rapid clearance from blood of mice. Virology (2000) 2.59
Selection of multiple human immunodeficiency virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral protease. Proc Natl Acad Sci U S A (1994) 2.59
Nucleotide sequence of the 5' noncoding region and part of the gag gene of Rous sarcoma virus. J Virol (1982) 2.53
The leader sequence of the subgenomic mRNA's of Rous sarcoma virus is approximately 390 nucleotides. J Virol (1982) 2.51
Temporal analyses of virus replication, immune responses, and efficacy in rhesus macaques immunized with a live, attenuated simian immunodeficiency virus vaccine. J Virol (1998) 2.49
A molecularly cloned, pathogenic, neutralization-resistant simian immunodeficiency virus, SIVsmE543-3. J Virol (1997) 2.46
Alpha/beta interferon protects adult mice from fatal Sindbis virus infection and is an important determinant of cell and tissue tropism. J Virol (2000) 2.41
Loss of functional KATP channels in pancreatic beta-cells causes persistent hyperinsulinemic hypoglycemia of infancy. Nat Med (1996) 2.40
Leaf Age as a Determinant in Stomatal Control of Water Loss from Cotton during Water Stress. Plant Physiol (1975) 2.40
Functionally inert HIV-specific cytotoxic T lymphocytes do not play a major role in chronically infected adults and children. J Exp Med (2000) 2.31
Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge. J Virol (2001) 2.30
Imprinting mutations in the Beckwith-Wiedemann syndrome suggested by altered imprinting pattern in the IGF2-H19 domain. Hum Mol Genet (1995) 2.27
V3 loop of the human immunodeficiency virus type 1 Env protein: interpreting sequence variability. J Virol (1993) 2.27
Pathogenic diversity of simian immunodeficiency viruses. Virus Res (1994) 2.27
Antigenic relatedness between glycoproteins of human respiratory syncytial virus subgroups A and B: evaluation of the contributions of F and G glycoproteins to immunity. J Virol (1987) 2.26
Nucleotide sequence analysis of feline immunodeficiency virus: genome organization and relationship to other lentiviruses. Proc Natl Acad Sci U S A (1989) 2.21
Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination. Proc Natl Acad Sci U S A (1997) 2.20
Characterization of responding cells in oxidative mitogen stimulation. II. Identification of an Ia-bearing adherent accessory cell. J Immunol (1980) 2.19
Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140. J Virol (2001) 2.16
Factors affecting thymic function after allogeneic hematopoietic stem cell transplantation. Blood (2001) 2.15
Specific restrictions in the progression of Venezuelan equine encephalitis virus-induced disease resulting from single amino acid changes in the glycoproteins. Virology (1995) 2.14
Attenuating mutations in the E2 glycoprotein gene of Venezuelan equine encephalitis virus: construction of single and multiple mutants in a full-length cDNA clone. Virology (1991) 2.13
Effects of anti-Ia sera on mitogenic responses. II. Differential expression of the Ia marker on phytohemagglutinin and concanavalin A-reactive T cells. J Exp Med (1976) 2.12
Analysis of retroviral protease cleavage sites reveals two types of cleavage sites and the structural requirements of the P1 amino acid. J Biol Chem (1991) 2.11
env genes of avian retroviruses: nucleotide sequence and molecular recombinants define host range determinants. Virology (1986) 2.11
Antigenic relationships of murine coronaviruses: analysis using monoclonal antibodies to JHM (MHV-4) virus. Virology (1983) 2.11
Kin recognition and the 'armpit effect': evidence of self-referent phenotype matching. Proc Biol Sci (2000) 2.04
Evolutionary variants of the human immunodeficiency virus type 1 V3 region characterized by using a heteroduplex tracking assay. J Virol (1997) 2.04
Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas. Ann Surg Oncol (2001) 2.01
Nuclease mechanism of the avian retrovirus pp32 endonuclease. J Virol (1986) 2.01
Sindbis virus mutants selected for rapid growth in cell culture display attenuated virulence in animals. Science (1984) 2.00
TENTATIVE CLASSIFICATION OF SYMPTOMATIC TYPES OF "TOMATO POCKETS". Plant Physiol (1930) 2.00
AGRANULOCYTOSIS IN TWO PATIENTS RECEIVING PHENYLINDANEDIONE. Can Med Assoc J (1953) 1.98
Immunity to influenza A virus infection in young children: a comparison of natural infection, live cold-adapted vaccine, and inactivated vaccine. J Infect Dis (1986) 1.97
Evidence for increased T cell turnover and decreased thymic output in HIV infection. J Immunol (2001) 1.97
Neutralization escape in human immunodeficiency virus type 1-infected long-term nonprogressors. J Infect Dis (1999) 1.96
Molecular analysis of Sindbis virus pathogenesis in neonatal mice by using virus recombinants constructed in vitro. J Virol (1988) 1.96
In vitro synthesis of infectious venezuelan equine encephalitis virus RNA from a cDNA clone: analysis of a viable deletion mutant. Virology (1989) 1.93
Recombinant adeno-associated viral vectors mediate long-term transgene expression in muscle. Hum Gene Ther (1997) 1.93
Molecular cloning of feline immunodeficiency virus. Proc Natl Acad Sci U S A (1989) 1.92
Serological and functional evidence for further subdivision of the I regions of the H-2 gene complex. Cold Spring Harb Symp Quant Biol (1977) 1.91
Comparison of long-term systemic and secretory antibody responses in children given live, attenuated, or inactivated influenza A vaccine. J Med Virol (1985) 1.88
Primary ventricular fibrillation complicating acute myocardial infarction. Am J Cardiol (1971) 1.88